Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935931 · ClinicalTrials.gov registry record · Early Phase 1
Naltrexone Neuroimaging
A Early Phase 1 study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT04935931: Completed Early Phase 1 study, sponsored by Children's Mercy Hospital Kansas City.
NCT04935931 is a Early Phase 1 study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 13 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04935931, a Early Phase 1 study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid antagonism in adolescents with ED. Modulation of brain activation will be examined in regions of interest by fMRI using a food-specific and general reward task in adolescents with ED in a pre/post design.
Primary Outcome
Change in %BOLD following single dose naltrexone (post-pre) within individuals during passive food view task in the nucleus accumbens
Interventions
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2022-06-30 |
| Phase | Early Phase 1 |
What the finished NCT04935931 record still lists
NCT04935931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Naltrexone is the first listed.
NCT04935931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04935931 about?
NCT04935931 is a clinical study titled "Naltrexone Neuroimaging". The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid antagonism in adolescents with ED. Modulation of brain activation will be examined in regions of interest by fMRI using a food-specific and general reward task in adolescents with ED in a pre/post design.
What is the current status of trial NCT04935931?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2021-07-16. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04935931?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT04935931?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04935931's enrollment target sits among peer trials
13 1504th of 2000 higher than 472 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI